Wyeth submits bazedoxifene, desvenlafaxine NDAs

WYE submitted NDAs to FDA for bazedoxifene to prevent postmenopausal osteoporosis and desvenlafaxine to treat moderate to severe vasomotor symptoms associated with menopause. The submission of bazedox...